Chronic treatment with phenelzine and other irreversible monoamine oxidase inhibitors downregulates I2-imidazoline receptors in the brain and liver.
Alemany
R
R
Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain.
Olmos
G
G
García-Sevilla
J A
JA
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003010:Clorgyline / Q000008:administration & dosage / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000378:metabolism; D015536:Down-Regulation; D004790:Enzyme Induction; D007093:Imidazoles / Q000378:metabolism; D054755:Imidazoline Receptors; D007520:Isocarboxazid / Q000008:administration & dosage / Q000494:pharmacology; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D010624:Phenelzine / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011955:Receptors, Drug / Q000187:drug effects* / Q000378:metabolism; D014191:Tranylcypromine / Q000008:administration & dosage / Q000494:pharmacology
D007093:Imidazoles; D054755:Imidazoline Receptors; D008996:Monoamine Oxidase Inhibitors; D011955:Receptors, Drug; D007520:Isocarboxazid; D014191:Tranylcypromine; D003577:Cytochrome P-450 Enzyme System; D003010:Clorgyline; D010624:Phenelzine